Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMICUTE: Amivantamab Plus Monochemotherapy in Platinum-Unfit EGFR exon20ins NSCLC
NCT07392658Phase 2Recruiting
- Sponsor
- Fondazione Ricerca Traslazionale
- Start
- Dec 2025
- Primary completion
- Oct 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of amivantamab in non-small cell lung cancer (NSCLC), sponsored by Fondazione Ricerca Traslazionale. Started Dec 2025; status: recruiting.
02
Drugs
amivantamab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07392658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07392658.